{
  "ticker": "EIQ",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02968129",
  "id": "02968129",
  "pages": 2,
  "price_sensitive": true,
  "date": "20250710",
  "time": "1022",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250710/pdf/06lnxn963xh4g1.pdf",
  "summary": "### Summary of Material Information:  \n\n- **Reseller Agreement with SARC MedIQ**: Significant expansion of **EchoSolv AS** distribution in the US through SARC MedIQ's network of **300+ healthcare facilities** and **1,500+ physicians**.  \n- **Revenue Model**: Initial **per-scan fee** from hospitals/clinics, with **renegotiated higher rates** upon securing Category III and Category I CPT codes (aligned with prior guidance).  \n- **Commercial Benefits**: Faster market access, **lower sales/distribution costs**, potential **predictable revenue stream** in coming quarters.  \n- **Integration Progress**: Sales force training advanced, integration into SARC MedIQ\u2019s network imminent.  \n- **Strategic Impact**: Builds on existing partnerships (**ScImage, MedAxiom**) to boost US adoption of EchoSolv AS.  \n\n*No material financial figures or trading-sensitive dates disclosed.*",
  "usage": {
    "prompt_tokens": 1321,
    "completion_tokens": 190,
    "total_tokens": 1511,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-10T00:59:05.695775"
}